What is Turnstone Biologics Corp (TSBX)?

Turnstone Biologics Corp (TSBX) Stock Analysis

$0.355

+0.005 (+1.43%)At close

Loading chart…

High: 0.365
Open: 0.350
VWAP: 0.36
Vol: 283.77K
Mkt Cap: 69.15M
Low: 0.350
Amount: 101.21K
EV/EBITDA, TTM: 0.57

Turnstone Biologics Corp. is a biotechnology company. The Company has been focused on the development of a differentiated approach to treating and curing patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy. It has discontinued all sponsored clinical studies evaluating TIDAL-01 for all indications, and pursuit of strategic alternatives to enhance and preserve stockholder value, which may include exploration and evaluation of strategic options like a merger, reverse merger, other business combinations, sale of assets, licensing, or other strategic transactions.

www.turnstonebio.com

Valuation Metrics

The current forward P/E ratio for Turnstone Biologics Corp (TSBX) is -1.58, compared to its 5-year average forward P/E of -0.83.

Forward P/E

Fair

5Y Average P/E

-0.83

Current P/E

-1.58

Overvalued

0.05

Undervalued

-1.71

Forward EV/EBITDA

Fair

5Y Average EV/EBITDA

0.16

Current EV/EBITDA

0.57

Overvalued

0.88

Undervalued

-0.57

Forward P/S

Strongly Undervalued

5Y Average P/S

0.00

Current P/S

0.00

Overvalued

0.00

Undervalued

0.00

Alphio AI Price Scenarios for TSBX

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

Bull

Bull · 25%TSBX

$0.39

Scenario price

Base

Base · 50%TSBX

$0.33

Scenario price

Bear

Bear · 25%TSBX

$0.26

Scenario price

Events Timeline

2025-08-11 (ET)